GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: SB- 773812 60 mg
Drug: SB- 773812 120 mg
Drug: Placebo

First Posted Date: 2007-07-12

Last Posted Date: 2017-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT00500201

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

Phase 1

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: SB-485232
Drug: Rituximab

First Posted Date: 2007-07-12

Last Posted Date: 2017-07-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00500058

Locations: 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States

Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK233705

First Posted Date: 2007-07-12

Last Posted Date: 2017-08-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9

Registration Number: NCT00500461

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2007-07-11

Last Posted Date: 2018-03-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 453

Registration Number: NCT00499707

Locations: 🇳🇿
GSK Investigational Site, Wellington, New Zealand

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A.
Biological: Infanrix hexa.
Biological: Meningococcal vaccine GSK134612.
Drug: Paracetamol.

First Posted Date: 2007-07-04

Last Posted Date: 2019-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 750

Registration Number: NCT00496015

Locations: 🇨🇿
GSK Investigational Site, Znojmo, Czechia

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK189075
Drug: Placebo

First Posted Date: 2007-07-03

Last Posted Date: 2017-10-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 250

Registration Number: NCT00495469

Locations: 🇺🇦
GSK Investigational Site, Vinnitsa, Ukraine

15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.

Phase 1

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: SB-649868
Drug: Placebo
Drug: Simvastatin

First Posted Date: 2007-07-03

Last Posted Date: 2017-08-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00495729

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

Bioequivalence and Food Effect Study in Healthy Volunteers

Phase 1

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: Formulation A
Drug: Formulation B
Drug: Formulation C
Drug: Formulation D
Drug: Formulation E
Drug: Formulation F
Drug: Formulation G